At first, the swing moves steadily with your help. But the moment you stop pushing, it slows down… then swings right back. That’s what stopping GLP-1 medications can feel like. While you're on them, appetite fades, weight drops, and you finally feel in control. But once the meds stop, hunger returns, cravings creep in, and the weight can start swinging back fast.

So what are you supposed to do?

Not to worry, this blog uncovers these questions and guides on what to do after you stop taking GLP-1 medications.

GLP-1 medications have reshaped the weight loss landscape: Drugs like Mounjaro, Wegovy, and Rybelsus are no longer just for managing diabetes, they’ve become some of the most effective tools for people trying to lose significant weight. For many, they work remarkably well. Clinical studies consistently show that people on GLP-1 medications lose upto 21% of their total body weight, reduce cravings, improve their metabolic health, and gain better control over emotional and binge eating.

For those who’ve experienced life-changing weight loss on these treatments, it’s a tough question. Many are surprised, and disappointed by how quickly the benefits seem to fade once the drug is discontinued. This blog unpacks what really happens after stopping GLP-1s, backed by clinical evidence, expert insights, and real-world data. Most importantly, it offers guidance on how to maintain your progress long-term.

GLP-1 receptor agonists such as semaglutide (Ozempic, Wegovy), liraglutide (Saxenda), and tirzepatide (Mounjaro) mimic a naturally occurring hormone in the body. These drugs work by slowing down digestion, reducing appetite, and regulating blood sugar, which in turn leads to decreased food intake and increased feelings of fullness. They also appear to influence reward centers in the brain, which reduces emotional and binge eating.Clinical trials offer compelling evidence of their effectiveness.

In the STEP 1 trial, patients taking 2.4 mg of semaglutide weekly lost an average of 14.9% of their body weight over 68 weeks. In another study evaluating tirzepatide, participants experienced up to 22.5% total body weight loss. Alongside the weight reduction, users often see dramatic improvements in blood pressure, cholesterol levels, and inflammation.

This level of success has made GLP-1 medications a transformative option for those struggling with obesity, until they stop taking it.

Weight Regain Is Common and Often Substantial

One of the most consistent findings across clinical trials is the return of weight after GLP-1 medications are stopped. In the STEP 1 extension trial, participants who discontinued semaglutide regained an average of 11.6% of their body weight within a year. This represented roughly two-thirds of the weight they had previously lost. Their net weight loss, a year after stopping, dropped from nearly 15% to just about 5%.

Real-world data backs this up. A 2024 analysis of over 20,000 patients using GLP-1 drugs found that 17–18% of users regained all the weight they had lost and sometimes even more, within a year of discontinuation. Meanwhile, about 56% managed to maintain some or all of their weight loss. While that’s encouraging, it still means that nearly half of patients saw partial or full reversal of their progress.

Hunger and Cravings Return in Full Force

One of the primary benefits of GLP-1 medications is how they suppress appetite and reduce "food noise”, the constant thoughts about food that many people with obesity experience. When the medication is stopped, hunger hormones such as ghrelin surge back, increasing cravings and making portion control more difficult. Many individuals report a dramatic increase in appetite and find themselves eating more than they intended, despite wanting to stay on track.

Experts often note that the return of these intense cravings can feel overwhelming. Without the medication, it takes more conscious effort and external support to manage hunger cues and stay within a calorie deficit.

The Body Actively Tries to Regain Lost Weight

The human body is biologically wired to maintain a certain “set point” weight. When weight is lost especially rapidly, as it often is with GLP-1 medications, the body responds by slowing metabolism, increasing hunger, and conserving energy. This phenomenon is well-documented and is one reason why people tend to regain weight after successful diets or drug therapies.

One meta-analysis found that patients who lost 8–16 kilograms on GLP-1 drugs typically regained 6–9 kilograms within a year after stopping. The body views weight loss as a threat to survival, and its hormonal and neurological responses are designed to encourage weight regain.

Health Improvements Also Regress

The benefits of GLP-1 medications go beyond weight. While on treatment, many patients see improved blood sugar control, lower blood pressure, better lipid profiles, and reductions in markers of inflammation. But these benefits are closely tied to weight loss. When the weight returns, so do the health risks.

In the STEP trial, patients with prediabetes who had reversed their condition while on semaglutide relapsed within a year of stopping treatment. Blood pressure and cholesterol levels also crept back toward their pre-treatment baselines. Although some markers, such as inflammation levels, remained slightly improved, most of the cardiometabolic gains diminished along with the weight loss.

GLP-1 drugs don’t just cause weight loss, they make it easier to eat less, feel full faster, and avoid overeating. Once the medication is withdrawn, all those benefits disappear unless they’re replaced by strong behavioral habits and lifestyle strategies.

Physiologically, stopping the drug causes appetite to increase. Psychologically, it becomes more difficult to resist temptation. Metabolically, your body burns fewer calories at rest after losing weight. Together, these forces create a perfect storm for weight regain, especially if there’s no plan in place to transition off the drug

The good news: yes, it’s possible to maintain your weight after stopping GLP-1s, but it requires intentional planning and support.

One effective strategy is to taper off the medication gradually rather than stopping abruptly. In a recent observational study from Denmark, patients who slowly reduced their semaglutide dose over nine weeks while receiving structured nutrition, exercise, and behavioral coaching were able to maintain their weight loss. Six months after stopping the drug completely, their weight remained stable, with some participants even continuing to lose weight.

Other patients maintain success by continuing with lower doses of medication, switching to alternative drugs like metformin or SGLT2 inhibitors, or engaging in intensive lifestyle programs. The key is to replace pharmaceutical support with behavioral systems, whether that means structured meal plans, regular physical activity, coaching, or ongoing medical follow-ups.

The GLP-1 landscape in India has shifted rapidly. Eli Lilly officially launched Mounjaro in India in early March 2025, and Wegovy followed in June 2025, both available in pharmacies by prescription. Many patients also access semaglutide through Rybelsus, the oral version, or through Ozempic, which Indian regulators have approv.ed for diabetes

Book your free consultation with Voy’s expert care team. We’ll help you taper safely, build habits that last, and maintain your results for life.

Disclaimer: GLP-1 medications should only be taken under the guidance of a qualified healthcare professional. At Voy, we strongly advise against the use of any GLP-1 therapy without proper medical consultation, as unsupervised use may lead to adverse side effects or health complications.